The Fas/Fas ligand system and cancer

被引：53

作者：

Abrahams, VM ^{[1
]}

Kamsteeg, M ^{[1
]}

Mor, G ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA

来源：

MOLECULAR BIOTECHNOLOGY | 2003年 / 25卷 / 01期

关键词：

FasL; ovarian cancer; secreted FasL; apoptosis;

D O I：

10.1385/MB:25:1:19

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The Fas/FasL system has been suggested to play an important role in the establishment of immune privilege status for tumors. by inducing Fas-mediated apoptosis in tumor-specific lymphocytes. However, the role of cell-surface expressed FasL in tumor cell protection has recently become controversial. Our laboratory has focused on the study of the role of the Fas/FasL system in the normal tissue remodeling of the female reproductive tract and in immune-privileged organs. Our studies have demonstrated a connection between sex hormones and the regulation of the Fas/FasL pathway in immune and reproductive cells. More recently, we have investigated the resistance of tumor cells to Fas-mediated apoptosis. We have also characterized a new form of FasL, different from the classical membranal form, which is secreted by ovarian cancer cells. In this review we describe the main techniques used in these studies.

引用

页码：19 / 30

页数：12

共 41 条

[21] Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex [J].

Krueger, A ;

Schmitz, I ;

Baumann, S ;

Krammer, PH ;

Kirchhoff, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (23) :20633-20640

[22] Bcl-2 relieves the trans-repressive function of the glucocorticoid receptor and inhibits the activation of CPP32-like cysteine proteases [J].

Miyashita, T ;

U, M ;

Inoue, T ;

Reed, JC ;

Yamada, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 233 (03) :781-787

[23] FAS (CD95) PARTICIPATES IN PERIPHERAL T-CELL DELETION AND ASSOCIATED APOPTOSIS IN-VIVO [J].

MOGIL, RJ ;

RADVANYI, L ;

GONZALEZQUINTIAL, R ;

MILLER, R ;

MILLS, G ;

THEOFILOPOULOS, AN ;

GREEN, DR .

INTERNATIONAL IMMUNOLOGY, 1995, 7 (09) :1451-1458

[24] Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen [J].

Mor, G ;

Kohen, F ;

Garcia-Velasco, J ;

Nilsen, J ;

Brown, W ;

Song, J ;

Naftolin, F .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 73 (05) :185-194

[25] Macrophages, estrogen and the microenvironment of breast cancer [J].

Mor, G ;

Yue, W ;

Santen, RJ ;

Gutierrez, L ;

Eliza, M ;

Berstein, LM ;

Harada, N ;

Wang, JP ;

Lysiak, J ;

Diano, S ;

Naftolin, F .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1998, 67 (5-6) :403-411

[26] Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis [J].

Mor, G ;

Straszewski, S ;

Kamsteeg, M .

BIOCHEMICAL PHARMACOLOGY, 2002, 64 (09) :1305-1315

[27]

Mor G, 1998, AM J REPROD IMMUNOL, V40, P89

[28] FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex [J].

Muzio, M ;

Chinnaiyan, AM ;

Kischkel, FC ;

ORourke, K ;

Shevchenko, A ;

Ni, J ;

Scaffidi, C ;

Bretz, JD ;

Zhang, M ;

Gentz, R ;

Mann, M ;

Krammer, PH ;

Peter, ME ;

Dixit, VM .

CELL, 1996, 85 (06) :817-827

[29] Apoptosis by death factor [J].

Nagata, S .

CELL, 1997, 88 (03) :355-365

[30] FAS AND FAS LIGAND - A DEATH FACTOR AND ITS RECEPTOR [J].

NAGATA, S .

ADVANCES IN IMMUNOLOGY, VOL 57, 1994, 57 :129-144

← 1 2 3 4 5 →